linjc16/ctgov huggingface dataset:
In Vitro Fertilization Outcomes in Metabolic Syndrome

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to examine the effect of metabolic syndrome in over-weight women on IVF treatment outcomes.

Detailed Description
-----------------
This porpuse of the study is to examine the physiology of CRP during the IVF cycle in and to evaluated the effect of CRP in patient with and without metabolic syndrome on IVF outcomes

Official Title
-----------------
The Influence of Metabolic Syndrome on in Vitro Fertilization Treatment Outcome

Conditions
-----------------
Metabolic Syndrome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: women undergoing ivf treatment Exclusion Criteria: inflammatory disease acute conditions

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| women with metabolic syndrome<br>women undergoing ivf treatment who have BMI>25 and meet the criteria for metabolic syndrome | |
| women without metabolic syndrome<br>women undergoing ivf treatment who have BMI>25 and who do not meet the criteria for metabolic syndrome | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| success or failure of ivf treatment | success or failure of a treatment will be determined by beta-Human chorionic gonadotropin test, number of oocyte retrieved or fertilized and embryos quality. | within 1 year from intiation of ivf treatment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| blood levels of C-reactive protein |  | within 1 year from initiation of ivf treatment | 
| follicle liquid levels of C-reactive protein |  | within 1 year from initiation of ivf treatment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
metabolic syndrome, in vitro fertilization, c reactive protein, over-weight women, ovarian stimulation
Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of Intravenous WCK 771

Study Overview
=================
Brief Summary
-----------------
The present study is planned to assess the safety and pharmacokinetic profile in normal healthy subjects in US for WCK 771 with doses ranging from 600 mg to 1000 mg BID for 5 days. In the proposed Phase I MAD study, a subject will be administered 600mg, 800mg, and 1000mg WCK 771 BID for 5 days (Ten doses) or an identical placebo as intravenous infusion.

Official Title
-----------------
Phase-I, Double-blind, Randomized, Placebo-controlled Single Center Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of Intravenous WCK 771 in Adult Healthy Human Volunteers

Conditions
-----------------
Bioavailability

Intervention / Treatment
-----------------
* Drug: WCK 771 IV Infusion
* Other: Placebo IV Infusion


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Have a Body Mass Index (BMI) between 18 and 32 (both inclusive), calculated as weight in kg/height in m2 Have no significant diseases or clinically significant abnormal findings during screening, medical history, physical examination, laboratory evaluations and ECG recordings Exclusion Criteria: Known hypersensitivity or idiosyncratic reaction to quinolones or any other related drugs Any history or evidence of disease or condition which might compromise the haemopoietic, renal, hepatic, endocrine, pulmonary, central nervous, cardiovascular, immunological, dermatological, gastrointestinal or any other body system Use of any prescription drug within 14 days prior to start of the study (check-in) and nonprescription drug within 7 days prior to start of study (check-in)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Sequential Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: WCK 771<br>WCK 771 600mg, 800mg, and 1000mg WCK 771 BID. Dosage form : IV Infusion | Drug: WCK 771 IV Infusion<br>* subjects will receive intravenous infusion of WCK 771<br>|
| Placebo Comparator: Placebo infusion<br>Matching Placebo administered as IV infusion | Other: Placebo IV Infusion<br>* subjects will receive matching placebo intravenous infusion<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To evaluate the safety & tolerability of multiple doses of WCK 771 | By monitoring the adverse events reported | Day 12 | 
| To evaluate the pharmacokinetics of multiple doses of WCK 771 | Measuring Cmax Maximum observed plasma concentration. | Day 5 |
Development of an Instrumental Activities of Daily Living Scale

Study Overview
=================
Brief Summary
-----------------
This study is to develop an IADL Scale for patients with SCI (IADL-SCI) and examine its psychometric properties in three years.

Detailed Description
-----------------
This study is to develop an IADL Scale for patients with SCI (IADL-SCI) and examine its psychometric properties in three years. In the first year, we will devote ourselves to the development of IADL-SCI - first version. About 150 patients will be recruited in this year. In the second year, the study will be focused on investigating the psychometric properties of IADL-SCI in order to construct the formal version of IADL-SCI in about 120 patients with stable condition. In the third year, we will be engaged in analyzing and comparing the psychometric properties of the three IADL scales (IADL-SCI, Frenchay Activities index, and Lawton IADL) to confirm that IADL-SCI is the best among the three. About 50 inpatients receiving rehabilitation will be recruited in this year.

Official Title
-----------------
Development of an Instrumental Activities of Daily Living Scale for Patients

Conditions
-----------------
Spinal Cord Injury

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with spinal cord injury Exclusion Criteria: patients with other major diseases (e.g., cancer)

Ages Eligible for Study
-----------------
Minimum Age: 0 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
psychometrics, activities of daily living
Effect of an Exercise Program of the Scapular Muscle Stabilizers in Amateur Kayakers Shoulder Pain

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether a specific strengthening program for the stabilizing scapular muscle can reduce shoulder pain of amateur kayaker.

Conditions
-----------------
Shoulder Pain

Intervention / Treatment
-----------------
* Procedure: Exercise program of the scapular muscle stabilizers


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: There Have Been practicing kayaking over 3 years. There Have Been shoulder pain during sports at least 1 month of evolution Exclusion Criteria: Shoulder pain was caused by a traumatic injury. To be in medical, pharmacological or shoulder physiotherapy treatment during the study. To have been surgically intervened in the shoulder

Ages Eligible for Study
-----------------
Minimum Age: 14 Years
Maximum Age: 30 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Exercise program<br> | Procedure: Exercise program of the scapular muscle stabilizers<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in pain level during kayakergometer test |  | participants will be followed for the duration of kayakergometer test, an expected average of 30 minutes | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| change in the time of appearance of the symptoms during kayakergometer test. |  | participants will be followed for the duration of kayakergometer test, an expected average of 30 minutes | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
strength training, scapular stabilization, kayakers.
The Presence of Microbes in the Sperm and Their Impact on Sperm Capacitation and IVF Treatment

Study Overview
=================
Brief Summary
-----------------
Study Goals: Finding the prevalence of bacteria of the sperm in an innovative and more accurate methode Understanding the effect of microbes on the process of capacitation The impact of microbes in the sperm on IVF success rate Finding the incidence of vaginal bacteria and their relationship to bacteria of the sperm The impact of vaginal flora on IVF success rate

Detailed Description
-----------------
Prospective non interventional study in the Department of Life Sciences, Bar-Ilan University and IVF Unit at Meir Hospital. The control group consisting of 50 semen samples from men with no sperm problems and 50 vaginal samples from their partners. The study group consisting of 50 semen samples from men with male fertility problems and 50 vaginal samples from their partners. The semen taken from the remains after fertilization of the IVF laboratory. (Liquid otherwise routinely thrown). Vaginal samples taken from women undergoing IVF treatment under anesthesia after informed consent. Enrollment also collect the following data: age, race, chronic illnesses, past surgeries and former fertility treatments. Data will be collected through anamnesis of the patient or the medical file after consent.

Official Title
-----------------
The Presence of Microbes in the Sperm and Their Impact on Sperm Capacitation and IVF Treatment

Conditions
-----------------
Infertility

Intervention / Treatment
-----------------
* Other: no intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male and female undergoing fertility treatments Exclusion Criteria: Male and female not undergoing fertility treatments

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Control- semen<br>Semen of fertile men | Other: no intervention<br> <br> |
| Control- vaginal discharge<br>Vaginal discharge of partners of fertile men | Other: no intervention<br> <br> |
| Case-semen<br>Semen of infertile men | Other: no intervention<br> <br> |
| Case- vaginal discharge<br>Vaginal discharge of partners of infertile men | Other: no intervention<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The percent of successful IFV treatments | Using 16-S Ribosomal RNA analysis to quantify and compare (type and percentages) of bacterial components in sperm samples from fertile and infertile men and their impact on IVF treatments success rate | 24 months |
Post-COVID-19 Chronic Fatigue Syndrome

Study Overview
=================
Brief Summary
-----------------
Fatigue is recognized as one of the most commonly presented long-term complaints in individuals previously infected with SARS-CoV-2.

Detailed Description
-----------------
It has become increasingly clear that infected patients have symptoms not only in the acute phase, but also after recovery from the initial infection. A recent meta-analysis including 4828 patients with post-COVID-19 showed that symptoms and post-acute sequelae of SARS-CoV-2 can persist weeks to months after the infection. These patients who reported persistent symptoms have been termed long haulers or described as having long COVID, post-acute COVID-19, persistent COVID-19 symptoms, post COVID-19 manifestations, long-term COVID-19 effects, post-acute sequelae of COVID-19 (PASC), or post-COVID-19 syndrome.

Official Title
-----------------
Post-COVID-19 Chronic Fatigue Syndrome

Conditions
-----------------
Post-COVID-19 Syndrome, Post-COVID Syndrome

Intervention / Treatment
-----------------
* Drug: Synthetic Vitamin B1


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age . 18 Male or female Post-Covid-19 Fatigue Exclusion Criteria: refusal

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Synthetic Vitamin B1<br>Synthetic Vitamin B1, 400 mg per day | Drug: Synthetic Vitamin B1<br>* Synthetic Vitamin B1 400 mg per day<br>|
| No Intervention: No intervention<br>No intervention | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Fatigue scale | chalder fatigue scale | one month | 
| Fatigue scale | chalder fatigue scale | two month |
Prophylactic Effect of Nifedipine on Further Decline in Renal Function in Patients Undergoing Open-Heart Surgery

Study Overview
=================
Brief Summary
-----------------
To compare renal function (51Cr-EDTA clearance) 48 hours post open-heart surgery (coronary bypass or valve surgery) in patients with impaired renal function after randomization to either nifedipine infusion at start of surgery and the following 24 hours or placebo (0.9% saline infusion). Study hypothesis is that nifedipine has a prophylactic effect on decline in renal function.

Official Title
-----------------
Postoperative Renal Function After Open-Heart Surgery in Patients With Impaired Renal Function Preoperatively. A Study of the Calcium Channel Blocker Nifedipine's Prophylactic Effect on Further Decline in Renal Function.

Conditions
-----------------
Kidney Failure, Chronic, Coronary Artery Disease

Intervention / Treatment
-----------------
* Drug: Nifedipine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients of either gender above 18 years of age. Patients with significant coronary stenosi(e)s (≥ 75% coronary artery lumen surface stenosi(e)s and / or aortic- or mitral valve vitriuim that are accepted for coronary artery bypass surgery and/or valve replacement surgery. Patients with impaired renal function, defined as increased serum- creatinine. Men: ≥ 150 µmol/l and Women: ≥130 µmol/l. Exclusion Criteria: Patients on maintenance hemodialysis Renal transplant patients Patients with ejection fraction ≤ 35% Patients with unstable angina pectoris

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Nifedipine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Primary efficacy endpoint is change in renal function, evaluated by 51Cr-EDTA clearance between 24 hours pre open-heart surgery and 48 hours post open-heart surgery. Sample size is 20, ten in each group. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in renal function after open-heart surgery, as measured by cimetidine refined serum creatinine clearance with measurements preoperatively and 2-6 hours, 20-24 hours and 44-48 hours postoperatively. Need for dialysis post-operatively. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Preventive Therapy, Calcium Channel Blockers, Kidney Failure, Chronic, Coronary Artery Bypass, Heart Valve Prosthesis Implantation
Endoscopy Quality Study

Study Overview
=================
Brief Summary
-----------------
This study seeks to establish factors that influence the view at endoscopy. To achieve this patients, who have been already booked for endoscopy, will complete a questionnaire prior to their procedure. Demographic and endoscopist factors will also be ascertained. The view at endoscopy will then be reviewed and scored against a rating scale, which will be validated as a first phase of the study. Factors can then be sought that are associated with a good endoscopic view.

Official Title
-----------------
Assessing the Quality of Upper Gastrointestinal Endoscopy - Factors That Affect it and Validation of a Bespoke Mucosal Visual Scale

Conditions
-----------------
Endoscopy

Intervention / Treatment
-----------------
* Other: Questionniare only


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Any patient booked for routine OGD Exclusion Criteria: Inpatient endoscopy Barretts surveillance endoscopy

Ages Eligible for Study
-----------------
Minimum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| All included participants<br>Patients that complete study questionnaire and have endoscopy recorded. | Other: Questionniare only<br>* A pre-procedure questionnaire will be completed by all participants<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| View seen at endoscopy | This is the quality of view seen at endoscopy based upon a bespoke scale | Endoscopy will be performed as booked for standard care. This will be the same day as consent. |
Point-of-care Ultrasound for Acute Kidney Injury

Study Overview
=================
Brief Summary
-----------------
It is aimed to determine prerenal, renal and postrenal diagnoses of patients with acute kidney injury with POCUS performed in the emergency department. Patients who presented to the emergency department and who have acute kidney injury (AKI) according to the KDIGO criteria will be evaluated and patients diagnosed with AKI will be included in the study. The diagnostic accuracy of POCUS with the AKI etiologies of the patients will be evaluated.

Official Title
-----------------
Diagnostic Accuracy of Point-of-Care Ultrasound in the Etiology of Acute Kidney Injury

Conditions
-----------------
Acute Kidney Injury

Intervention / Treatment
-----------------
* Diagnostic Test: Ultrasonography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: • AKI diagnosis according to KDIGO criteria Exclusion Criteria: Patients with end stage renal failure, Failure to perform POCUS in the first two hours of presentation of patient, Those with renal malignancy, Pregnant women, Renal transplantation patients, Patients with a single kidney, Those with polycystic kidney disease, Patients with nephrostomy, Patients who are referred from another center, Unable to perform adequate imaging, Patients who do not give consent for the study will be excluded.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Ultrasonography|Point-of-care ultrasound: Kidney length and echogenity, Bladder scanning VCI measures Lung B lines and effusion Cardiac measurements; EF, TAPSE, TR Vmax, Diameters, LV filling pressures|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The diagnostic accuracy of POCUS in the patients with AKI |  | One year |
Circadian Variation in Serum-progesterone Levels Following Controlled Ovarian Hyperstimulation.

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to investigate the circadian variation in serum-progesterone in women undergoing controlled ovarian stimulation.

Official Title
-----------------
Circadian Variation in Serum-progesterone Levels Following Controlled Ovarian Hyperstimulation.

Conditions
-----------------
Infertility

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women undergoing standard IVF/ICSI treatment. Exclusion Criteria: Previous participation in the study.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| serum progesterone levels |  | 12 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| serum LH levels |  | 12 hours | 
| serum estradiol levels |  | 12 hours | 
| 17-OH progesterone |  | 12-hours |